This guide covers the practicalities. What ARRS pharmacist roles look like in 2026, what PCNs can claim for, where the common delivery problems sit, and the route most networks take to turn the funding into reliable clinical capacity.

What the Additional Roles Reimbursement Scheme funds

ARRS is the funding stream under the Network Contract Direct Enhanced Service that lets PCNs claim back the cost of specific clinical and operational roles. NHS England sets the eligible role list, the reimbursement caps, and the supervision requirements. PCNs decide which roles to recruit and how to deploy them.

Clinical pharmacists and pharmacy technicians have been on the eligible list since the original 2019 framework and remain there in 2026. The roles are reimbursable at agreed maximum amounts covering salary, employer National Insurance, and employer pension contributions. The PCN does not absorb employment costs out of its core funding.

Pharmacist roles eligible under ARRS in 2026

Clinical pharmacist

A registered pharmacist working within general practice teams. Day-to-day work covers structured medication reviews, high-risk drug monitoring, repeat prescription management, long-term condition reviews, and triaging medicines queries from GPs and patients. Most PCNs deploy clinical pharmacists across more than one practice in the network.

Senior or advanced clinical pharmacist

A clinical pharmacist who is also an independent prescriber, usually with three to five years of post-registration experience and a clinical specialism. Cardiovascular. Respiratory. Frailty. Mental health. The reimbursement cap sits higher than for a standard clinical pharmacist, reflecting the prescribing scope and the supervisory contribution to the wider pharmacist cohort.

Pharmacy technician

A General Pharmaceutical Council-registered technician. The role centres on medicines reconciliation, repeat prescription processing, hospital discharge follow-up, audit data extraction, and supporting the clinical pharmacist team with non-clinical activity. A well-deployed technician removes hours of administrative load from clinical pharmacists. Every reimbursed pharmacist hour goes further.

Funding and reimbursement

Reimbursement is paid against actual employment cost up to the maximum reimbursable amount for that role and band. PCNs claim through their commissioner each quarter, evidenced by payroll records. Any cost above the cap falls to the PCN.

Two practical points that catch PCNs out:

• Reimbursement is for the role, not the individual. If a pharmacist leaves mid-quarter, the claim covers actual paid weeks, not the vacancy.
• Locum and agency staff are reimbursable, but only where the PCN can evidence employment arrangements meeting NHS England requirements. Most PCNs use a single managed-service partner to keep this audit-clean.

Common challenges PCNs face delivering ARRS pharmacist services

Funding is the easy part. Translating funded headcount into productive clinical work is where networks lose value.

Supervision capacity. Clinical pharmacists in primary care need clinical supervision. Senior pharmacists need clinical supervision from a prescriber. PCNs without an in-house senior pharmacist often end up paying twice. Once for the role, once for external supervision.

Practice variation. Six practices in a PCN can have six different prescribing systems, six approaches to repeat authorisation, and six different protocols for medication review documentation. Pharmacists spend their first weeks unpicking variation rather than delivering reviews.

Recruitment timelines. From advert to first clinic, the typical NHS recruitment cycle for a clinical pharmacist is twelve to eighteen weeks. ARRS funding is paid in arrears, so a delayed start delays the reimbursement.

Reporting overhead. PCNs need to evidence ARRS pharmacist activity, not just headcount. Capturing structured medication reviews, high-risk drug monitoring contacts, and saved GP appointments takes consistent data discipline. Usually a technician’s remit.

How to structure ARRS pharmacist delivery effectively

The networks that get the most clinical value from their ARRS pharmacist budget tend to share four practices.

1. Centralised governance. One supervising senior pharmacist, one set of clinical protocols, one shared documentation template across all practices in the network. Variation is paid for in pharmacist time.
2. Role pairing. Every clinical pharmacist paired with a technician for repeat prescription, reconciliation and audit support. Clinical pharmacist hours concentrate on tasks that only a prescriber can do.
3. Outcome tracking. Weekly capture of structured medication reviews completed, high-risk drug monitoring contacts, and prescribing changes made. Quarterly summary to the Clinical Director.
4. Cohort case discussions. Monthly multi-disciplinary cohort review across all PCN pharmacists, anchored by the senior pharmacist. Lifts clinical quality and reduces the supervision burden on individual practices.

When to use a managed-service provider

Networks usually consider an external ARRS partner in three situations.

• Recruitment risk. PCNs in regions with thin local pharmacist pools struggle to recruit directly and lose months of reimbursement waiting on candidates.
• Supervision gap. PCNs without an in-house senior pharmacist need external clinical supervision before the first pharmacist can prescribe.
• Governance overhead. PCN management teams report that ARRS pharmacist administration consumes a disproportionate share of Clinical Director time. Payroll. Professional indemnity confirmation. NHS England returns. Clinical audit.

A managed provider takes recruitment, supervision and governance off the PCN. The funding mechanic does not change. Reimbursement still flows from NHS England to the PCN. The operational lift is absorbed by the provider.

Where to start

If your PCN is at any of the three pinch points above, the most efficient first step is a one-call scoping conversation. Which roles are funded. Which practices in the network would benefit first. What governance you already have in place.

We provide that scoping as a free service. Visit our ARRS support service page to see how we deliver, or get in touch through our enquiry form.

The post ARRS Pharmacist Roles in 2026: A Practical Guide for PCNs appeared first on Virtual Pharmacist.

This guide covers what an SMR is, who qualifies, the seven-step framework most PCNs use, what good documentation looks like, and the operational mistakes that turn an SMR programme into a tick-box exercise.

What an SMR is, and what it is not

An SMR is a planned consultation where a clinician reviews every medicine a patient is taking, the reason each was started, whether it is still doing the job it was prescribed for, and what could be stopped, swapped, or dose-adjusted. It is documented. It changes prescribing. It is followed up.

It is not an annual repeat prescription review. It is not a chronic disease review where medication happens to come up. The clinical scope is wider, the documentation richer, and the time slot longer. Usually 30 to 45 minutes for a first SMR. 20 to 30 minutes for a follow-up.

Who qualifies for an SMR

NHS England priority cohorts are stable from year to year. PCNs should focus on:

• Care home residents
• Patients on 10 or more regular medicines
• People with frailty (Rockwood 6 or above)
• Patients on high-risk drugs (DOACs, NSAIDs in older adults, lithium, methotrexate, antipsychotics in dementia)
• Patients identified through searches for problematic prescribing combinations

In practice, most PCNs draw their first SMR cohort from care home residents. The patients are easy to identify, the polypharmacy is dense, and the clinical return on each review is high.

The seven-step approach

Most NHS regions teach a variant of the seven-step SMR model. The steps run roughly:

1. Identify the aim of the review with the patient. What do they want from their medicines?
2. Identify essential drug therapy. What must continue?
3. Identify non-essential or no-longer-effective therapy. What can stop?
4. Are objectives being met by the current drugs? What is the evidence of benefit?
5. Are there safety concerns. Adverse effects. Interactions. Monitoring gaps.
6. Is the medication regimen cost-effective. Generic substitution. Brand to generic.
7. Is the patient willing and able to take the medicines as prescribed.

The order is less important than completing each step. SMRs that skip step 1, the patient conversation, read like internal audits rather than reviews.

What good documentation looks like

A well-documented SMR has three things a thin one does not. First, the patient’s view of their medicines in their own words. Second, an explicit decision against each drug. Continue, stop, dose change, swap, consultant review, or patient declines. Third, a follow-up action with an owner and a date.

PCNs that audit their SMR documentation usually find the first item missing on the majority of reviews. The patient voice is the part that distinguishes an SMR from a prescribing review.

Where SMR programmes fail

Four failure modes account for most of the problems.

Reviews counted on the wrong code. The Network DES reimburses against specific SNOMED CT codes. Reviews coded under generic medication review SNOMEDs do not count, even when the underlying clinical work is identical. Annual audit catches this. Annual audit is too late.

No follow-up. A review without a follow-up is a recommendation in a vacuum. The pharmacist proposes stopping a statin. The GP never actions the change. The patient is back on it at the next prescription cycle.

One-shot model. Treating SMRs as one-off events instead of an ongoing programme means the next year’s reviews start from the same cohort baseline as the previous year.

Pharmacist isolation. A pharmacist doing 30 SMRs a week with no peer discussion drifts into routines that nobody else challenges. Monthly cohort discussion is what keeps SMR quality honest.

What an effective SMR cadence looks like

The PCNs that deliver SMR targets sustainably tend to share a few features.

Reviews are pre-booked. A pharmacist’s diary three weeks ahead has named SMR slots, with the patient cohort already identified through EMIS or SystmOne searches. Same-day SMRs squeezed between other appointments rarely meet the documentation bar.

Searches are run centrally. One person at PCN level extracts the eligible cohort each month and distributes it across practices. Practices that build their own searches end up with patchy criteria.

Documentation templates are shared. A single SMR consultation template, written once and refined together, removes variation between pharmacists and makes audit straightforward.

Outcomes are reported. Each quarter, the PCN reports number of SMRs completed, number of medicines stopped, number of medicines started, average prescribing cost change per patient, and number of patients escalated to GP or consultant review.

Where to get help

If your PCN is missing its SMR target, or finishing reviews that audit poorly, the usual remedy is not more pharmacist hours. It is structure. Cohort definition. Consultation templates. Supervision. Reporting.

We deliver SMR programmes end to end for PCNs. Pharmacist-led reviews, searches, templates, documentation, and quarterly reporting under one managed service. Our medication review service covers the operational lift, or get in touch for a scoping conversation.

The post Structured Medication Reviews in Primary Care: A 2026 Guide appeared first on Virtual Pharmacist.

This piece sets out where the savings come from, what work can move, what cannot, and why the role sometimes underdelivers.

Where the time savings come from

Three categories of work transfer cleanly.

Repeat prescription queries. A practice that does not actively manage repeats receives 50 to 200 medication queries a week through admin. Missed items. Mismatched quantities. Hospital discharge changes. A technician or pharmacist can handle 90% of these without GP input.

Long-term condition reviews. Hypertension, diabetes, asthma, COPD, anticoagulation. A pharmacist running structured reviews against agreed clinical pathways completes about 8 to 12 a day. Each one removes an appointment from the GP’s diary.

Medication-related admin. Hospital discharge reconciliation. High-risk drug monitoring reminders. QOF data entry tied to prescribing. Specialist initiation paperwork. Work that consumes 30 to 45 minutes of GP time each day reduces to oversight.

A clinical pharmacist with three to four days of practice time can typically release between 12 and 18 GP appointments a day across those three categories. That is the upper bound. The lower bound, what poorly-deployed pharmacists release, is closer to four to six.

The tasks that move well

Medication reviews of every kind. Repeat prescription authorisation against agreed protocols. Hospital discharge reconciliation. Triage of medicines queries from patients and community pharmacy. Anticoagulation reviews. Specific high-risk drug clinics (lithium, methotrexate, DMARDs). Annual long-term condition reviews where the pathway is well-defined.

Prescribing pharmacists with three or more years of post-registration experience can also take on:

• Hypertension titration
• Type 2 diabetes drug adjustment
• Statin initiation
• Anticoagulation initiation
• Asthma step-up under agreed criteria

The savings rise sharply when the pharmacist is an independent prescriber. The same review that ends with “GP to action” becomes a review that ends with the prescription written.

The tasks that do not move

Acute appointments where the diagnosis is in question. Anything safeguarding. Complex multi-morbidity where the trade-off is between conditions. End-of-life care decisions. Mental health where the pharmacist has no specialist training. New presentations.

Practices that try to push too far end up with the pharmacist doing GP-substitute work and the GP picking up the consequences. The line moves over time as the pharmacist gains experience. It does not move on day one.

Where the deployment fails

The same patterns show up across practices where the role underdelivers.

Pharmacist used as a triage filter, not a clinician. The pharmacist reviews 80 queries a day but every one ends with “discuss with GP”. Net workload moved: zero.

No protocols. The pharmacist cannot prescribe, cannot authorise repeats above a certain threshold, cannot decide on dose adjustments without sign-off. Each task generates a GP touch-point.

No clinical sessions. The pharmacist sits at a desk processing admin instead of running clinics. Patient-facing time is the part that releases GP appointments.

Practice habits unchanged. The receptionist still routes every medication query to the GP because that is what they did before. The pharmacist’s diary stays empty.

Recruiting the wrong band. A Band 7 clinical pharmacist with no prescribing rights cannot do the work a Band 8a independent prescriber can. Practices that try to save money on the band pay for it in throughput.

Getting deployment right

The practices that release the most GP time tend to share four things.

Job plan written in advance. Two to three days of patient-facing clinics. One day of admin and audit. Half a day of supervision. The pharmacist does not start until the job plan is signed off by the GP partners.

Reception trained on triage. Receptionists know which queries go to the pharmacist by default and which still go to the GP. New triage protocols sit on the receptionist’s desk in laminated form for the first three months.

Prescribing rights from week one. If the pharmacist is a prescriber, they prescribe. Practices that hold back prescribing rights “until trust is built” lose six months of throughput.

Monthly review of release figures. Number of GP appointments saved. Number of repeat prescription queries handled without GP touch. Number of long-term condition reviews completed. The data conversation is what keeps the role honest.

What to do next

If your practice has a clinical pharmacist but the workload has not shifted, the fix is rarely more hours. It is the deployment model. A short audit of where the pharmacist’s time actually goes, compared to the job plan they were hired against, usually identifies the gap within a morning.

We help practices and PCNs reduce GP workload through our fully managed pharmacist service: service design, delivery, and clinical governance under one managed contract. Our GP pharmacist support service delivers a governed clinical pharmacy service we are accountable for, and our clinical pharmacist support service covers the service-delivery side. Get in touch for a deployment review.

The post How Clinical Pharmacists Reduce GP Workload: A Practical Breakdown appeared first on Virtual Pharmacist.

This piece sets out where innovation funding comes from in 2026, what evaluators look for, and where most applications fall short.

What innovation funding actually covers

Innovation in NHS funding language usually means money outside core contract funding. That covers a wide range of programmes:

• NHS England transformation funds tied to specific national priorities (cardiovascular prevention, frailty, women’s health hubs)
• ICB innovation pots, which vary by region but typically run between £15,000 and £200,000 per award
• NHS England Transformation Directorate funding for clinical software, AI tools, and data infrastructure
• Academic Health Science Network programmes
• Charity-funded programmes (BHF, Diabetes UK, Cancer Research UK) for clinical pathway redesign
• Industry partnerships where a pharmaceutical or medical device company funds service evaluation work

The clinical case is usually well-articulated by the time a practice considers applying. The challenge is matching the case to the right funding stream.

The main routes in 2026

NHS England Service Development Funding remains the largest national pot. It funds time-limited transformation work, typically 12 to 24 months, with a clear scale-up expectation. Applications go through the ICB.

PCN-level innovation funding through ARRS-adjacent streams covers workforce-related innovation. A PCN that wants to pilot a frailty service across its practices can usually find money inside the ICB rather than going national.

NIHR funding suits practices that have a research question and the capacity to deliver to a research protocol. Different administrative burden, different reporting requirements, different timescales.

Industry partnerships are the most under-used route. A pharmaceutical sponsor will fund pathway optimisation work for conditions where their drug is involved (anticoagulation, diabetes, asthma), provided the practice can show patient-level outcome data at the end.

What evaluators look for

Four things, in order.

Defined patient cohort with measurable outcomes. “Reduce cardiovascular risk in our patients” is not a cohort. “Identify the 320 patients on our list with QRISK above 20% who are not on a statin, offer a clinic, achieve a 70% statin initiation rate” is a cohort.

Realistic delivery plan. The plan has named people, named systems, named clinical pathways. It says who will do the work, how long it will take, and what could go wrong.

Evaluation built in from day one. Not bolted on at month nine. The evaluation question is set at application stage. Baseline data is collected before the intervention starts.

Scale potential. Funders are not paying for one practice’s project. They are paying for something that, if it works, can be replicated elsewhere. The application has to say what that replication looks like.

The application work that matters

The clinical case writes itself. The work that wins funding is the operational detail behind it.

Data plan. Who pulls the baseline data. From which system. Refreshed how often. Compared against what.

Governance. Information governance approval. Caldicott. Ethics where relevant. Letter of support from the ICB clinical lead.

Resource plan. How much pharmacist time. How much GP time. Admin support. IT changes. Training requirements.

Budget. Real numbers per quarter, not a single annual figure. Underspend explanation. Underspend recovery plan.

Risk register. What could fail. What the mitigation is.

A clean 30-page application with these five elements completed will outperform a 60-page application with a long clinical introduction and thin operational detail.

Where most applications stumble

Three failure modes are common.

Vague outcome targets. “Improve patient experience” sets no measurable bar. Evaluators score it as zero.

Underestimated time costs. The clinical lead is named on the project but has no protected time. The work falls between sessions. Month six shows zero progress.

No evaluation partner. Practices try to evaluate their own work, with no academic or analytical partner. Funders increasingly want to see who is doing the analysis before they release the money.

Where to get help

Our fully managed innovation funding service supports practices and PCNs end to end. Identifying the right route. Writing the application. Delivering the project. Evaluating the outcomes. Our innovation funding service covers the practical side. Get in touch if you want to talk through a specific bid.

The post Innovation Funding for GP Practices: Routes and Eligibility in 2026 appeared first on Virtual Pharmacist.

Most practices have a process. Fewer have a process that survives the second pharmacist leaving and the third GP joining. This piece sets out what working high-risk drug monitoring looks like in 2026.

What counts as high-risk in primary care

NHS England guidance (covering the medicines-safety remit formerly held by NPSA) defines the headline list. In practice, the drugs that account for most monitoring failures are:

• DOACs (apixaban, rivaroxaban, edoxaban, dabigatran)
• Lithium
• Methotrexate
• Amiodarone
• DMARDs (azathioprine, leflunomide, hydroxychloroquine)
• Warfarin
• Antipsychotics in dementia patients
• Long-term NSAIDs in patients over 65 or with CKD

Each has different monitoring frequency requirements. None can be safely managed without a registered, dated bloods schedule. Most can be audited from EMIS or SystmOne in under 20 minutes.

Where monitoring fails

Three patterns recur.

Patients lost between systems. A patient starts methotrexate under rheumatology. Rheumatology assumes the GP will monitor. The GP assumes rheumatology is. The patient gets six months of methotrexate with no FBC.

Bloods done, results unreviewed. The phlebotomist takes the sample. The result lands in the GP’s inbox. Nobody is named as the person responsible for reviewing it against the monitoring criteria. The result sits unread.

Monitoring drift. The patient started at three-monthly. Bloods got six-monthly during a busy quarter. Six-monthly turned into nine-monthly. A year later, monitoring has fallen well below the prescribed cadence and nobody noticed.

Each pattern is a process failure. None of them are individual clinician failures.

Who is actually responsible

In most practices, three roles touch high-risk drug monitoring. The GP who prescribes (or holds prescribing responsibility from secondary care), the clinical pharmacist who runs the monitoring system, and the pharmacy technician who supports the admin work.

The clinical pharmacist is the role that holds the system together. The GP signs prescriptions. The pharmacist runs the patient list, the bloods schedule, the result review, and the GP escalation. The technician handles patient contact, blood form generation, and lab follow-up.

Practices without a pharmacist usually rely on EMIS or SystmOne searches managed by a partner GP. Workable, but the partner ends up doing pharmacist-level work at GP cost.

What a working monitoring system looks like

Five elements in combination.

A named patient list. Every patient on each high-risk drug, dated by the time of the next required check.

Searches refreshed weekly. The patient list updates itself from prescribing data. New starts appear automatically. Stops drop off after a verified discontinuation.

Bloods booking that does not depend on the patient. Letters and texts go out automatically when the next check date approaches. Three contacts before escalation. Phlebotomy appointments booked in batches once a fortnight.

Result review by named clinician. Every blood result has a named reviewer. The reviewer signs the result against agreed action criteria. Out-of-range results trigger immediate clinician contact, not a queue.

Quarterly audit. The pharmacist runs a quarterly audit of monitoring adherence. Percentage of patients with bloods within agreed intervals. Audit results go to clinical leads.

A practice that has all five does not have monitoring failures. A practice missing two or more usually does.

Running a high-risk drug audit

The audit itself is straightforward and worth running annually even where the system looks healthy.

Pull the list of patients on each high-risk drug. Cross-reference with the most recent monitoring blood. Calculate the percentage with bloods inside the prescribed monitoring window. Investigate the ones outside. Document the corrective action.

A first audit in a typical practice usually finds 15% to 25% of patients on high-risk drugs with overdue monitoring. After a year of corrective action, the figure should be below 5%.

When to call in support

If your practice has had two or more incident reports related to high-risk drug monitoring in the past 12 months, the system is the issue, not the people. The same applies if a CQC inspection has flagged monitoring as a concern.

We deliver high-risk drug monitoring as a managed clinical service, with our clinical pharmacist team operating under Virtual Pharmacist’s clinical governance. Our clinical pharmacist support service covers the full setup. Get in touch if you want a quick external review.

The post High-Risk Drug Monitoring in Primary Care: Roles and Workflow appeared first on Virtual Pharmacist.

This piece sorts the two apart. It also covers what good QOF support from a pharmacist looks like and where practices get the support badly wrong.

What pharmacists actually shift

A pharmacist working consistently in a practice for a year typically improves performance against the following QOF clusters.

Cardiovascular indicators. Blood pressure control in hypertension and diabetes. Lipid management. Anticoagulation in AF.

Respiratory indicators. Annual asthma reviews. Annual COPD reviews. Inhaler technique audits.

Diabetes. HbA1c targets. Foot checks for high-risk patients. Albumin-creatinine ratio testing.

Mental health. Annual physical health checks for patients on antipsychotics or with severe mental illness.

Prescribing-related QOF. Items like NSAIDs in patients with CKD, antibiotic prescribing rates, hypnotic prescribing trends.

The pattern across the high-impact indicators is consistent. They require a structured patient contact every 12 months. The contact has a defined clinical content. The data has to be recorded against a specific Read or SNOMED code.

Where the income and outcome match-up is best

Three indicator clusters give both income and clinical value back at roughly the same rate.

Anticoagulation in AF. Patients with AF need a CHA2DS2-VASc score and, where indicated, an anticoagulant. Practices that systematically work through their AF register usually find 5% to 15% of patients eligible for anticoagulation who are not on one. Starting them prevents strokes. It also moves the QOF indicator.

Hypertension control. The 140/90 (or 150/90 in older adults) target is clinically defensible. Patients who get to target through pharmacist-led titration clinics have measurably better cardiovascular outcomes.

Annual SMI physical health checks. Patients on antipsychotics have shorter life expectancy. The annual physical health check catches metabolic side effects early. Pharmacists running the checks pick up issues GPs are too rushed to see.

Where the income and outcome match-up is poor

Some indicators move income without moving outcomes much.

Personalised Care Adjustment (formerly known as exception reporting). Practices that systematically exception-report patients to hit the indicator add nothing clinically. The income arrives. The patient is no better off.

Coded reviews without clinical content. A diabetes review coded against the right SNOMED but completed in five minutes adds nothing the patient could not have done at home.

Some prescribing indicators where the underlying clinical question is more complex than the indicator allows.

A pharmacist who chases all QOF income without thinking about which indicators justify the time ends up doing work that scores well on Friday’s report and badly on Monday’s morbidity.

The QOF audit cycle pharmacists run well

The work pattern looks roughly like this.

April. Pull the prior year’s data. Identify indicators where the practice is below the upper threshold but above the lower. These are the ones where extra effort still earns income.

May to August. Targeted clinics against the prioritised indicators. Patient contact pre-booked. Templates set up. Coding agreed in advance.

September. Mid-year check. Are indicator scores tracking? Are patients showing up? What is going wrong?

October to January. Catch-up clinics on indicators that are below target. Outreach to patients who have not attended. Exception report only where clinically justified.

February to March. Final push on indicators still at risk. Audit data quality. Identify next year’s improvement targets.

A pharmacist running this cycle reliably picks up 3 to 7 indicators a year that would otherwise have under-performed.

What it looks like done badly

Pharmacist asked to “do QOF” with no defined indicators. The work fragments across every indicator and improves none.

QOF clinic that runs on the day income reports are due. The clinic catches up activity but misses outcome opportunities.

GP partners not engaged. The pharmacist identifies prescribing changes but cannot get sign-off from the partners. Patients miss interventions.

Coding errors not corrected. The pharmacist does the clinical work but the wrong SNOMED gets recorded. The work happens. The income does not arrive.

Where to start

If your practice’s QOF performance has slipped, or you have a sense the income is being earned at clinical cost, the fix is structural. A defined cycle of QOF improvement work, mapped against indicators where the income and outcomes both matter, run by a clinician with the time to do the patient-facing work properly.

Our fully managed quality and audits service covers QOF audit and improvement work end to end. Get in touch for a baseline assessment.

The post QOF Outcomes: Where Pharmacist Input Has the Biggest Impact appeared first on Virtual Pharmacist.

This piece sets out what a technician is, what they can run independently, where they free up pharmacist and GP time, and the deployment patterns that turn the role into a glorified prescription clerk.

What a technician is and is not

A pharmacy technician registered with the GPhC has completed a level 3 qualification, two years of pre-registration practice, and ongoing CPD. They are clinically qualified. They are not pharmacists. They cannot run medication reviews. They cannot make prescribing decisions.

What they can do, with appropriate training and supervision, is run the operational layer of medicines management. Repeat prescription processing. Hospital discharge reconciliation. Audit data extraction. Patient contact about routine medicines issues. Specific medication-related clinics under protocol.

What technicians can run independently

Six pieces of work move cleanly to a technician.

Repeat prescription processing. Authorising routine repeats against agreed criteria. Identifying patients due for review and routing them to the pharmacist or GP. Removing items no longer prescribed.

Hospital discharge reconciliation. Checking discharge letters against existing prescriptions. Identifying changes. Flagging clinically significant changes to the pharmacist. Updating prescribing records.

High-risk drug administration. Sending bloods reminders. Generating phlebotomy forms. Following up missed appointments. Updating the practice register.

Compliance and dosette work. Liaising with community pharmacy on dosette supply. Identifying patients who would benefit from compliance aids. Handling the paperwork.

Specific audit work. Pulling lists for prescribing audits. Cross-referencing prescribing data against guidelines. Producing audit reports.

Patient contact for routine queries. Answering questions about generic switches, supply problems, side effect concerns under protocol, repeat ordering, hospital prescriptions.

Where technicians free up pharmacist time

The unspoken rule of clinical pharmacist deployment in general practice is that the pharmacist’s time is worth most when they are doing prescribing-level clinical work. Every hour of pharmacist time spent on repeat authorisation or discharge reconciliation is an hour not spent on medication review or high-risk drug management.

A technician absorbs the operational layer. A clinical pharmacist with a technician partner runs roughly 30% more clinical contacts per week than the same pharmacist working alone.

In a six-practice PCN, the typical configuration is two clinical pharmacists and one full-time technician. Some PCNs run two-to-one ratios in either direction. The point is the pairing, not the precise ratio.

The deployment mistakes

Technician hired with no protected supervision. The role needs a named clinical supervisor (a pharmacist or senior pharmacist) and protected time for the supervision to happen. Practices that skip this end up with a technician working blind on tasks that need clinical oversight.

Technician used as a general admin. Front-line phone work. Booking appointments. Scanning. Filing. The role goes the way of any other administrative role and the medicines work it was meant to absorb stays with the pharmacist.

No agreed scope of practice. Without a written list of what the technician can authorise independently, every decision becomes a question to the pharmacist. Net time saved: zero.

Hired the wrong band. A technician straight out of training cannot run the operational layer of a busy practice without daily supervision. A senior accuracy-checking technician with five years of clinical pharmacy experience can.

Pairing technicians with pharmacists

The pairing model that works is straightforward.

Daily quick-fire handover, 15 minutes. What the technician picked up. What needs clinical input. What the pharmacist is working on. What is parked.

Weekly review of the agreed scope. Has anything new come up that needs to be added to the scope or escalated out of it?

Monthly audit of decisions. A sample of decisions the technician made. The pharmacist reviews for clinical safety. Adjustments to scope follow.

This pattern keeps the technician growing in scope without the pharmacist needing to supervise every individual decision.

Getting the role right

The practices and PCNs that get the most from their technician role tend to do three things on day one.

Write the scope of practice as a one-page document and put it on the technician’s desk. Update it quarterly.

Pair the technician with a named pharmacist supervisor, not a rotating group. Continuity of supervision matters more than the supervisor’s grade.

Track the work. Number of repeat prescriptions handled independently. Number of discharge reconciliations. Number of audits completed. The data is what justifies the role to GP partners.

Our fully managed pharmacy technician support service covers placement, supervision and clinical oversight under a single contract. Get in touch for a deployment review.

The post The Pharmacy Technician Role in GP Practices: Beyond Prescriptions appeared first on Virtual Pharmacist.

This piece sets out the pressures that consume the time, the structural fixes that work, and where outside support changes the day-to-day.

The role on paper

The Network DES specifies the CD as the named clinical leader of the PCN. Required time commitment ranges from 0.5 to 2 sessions a week, paid out of PCN core funding. The role covers clinical service delivery across the network, workforce decisions for ARRS roles, peer relationships between member practices, and the PCN’s interface with the ICB.

That is the description. The actual job is wider.

The pressures that actually consume the time

Practice politics. Six practices in a PCN means six sets of partners, six clinical lead voices, six histories with each other. Disputes over patient allocation, ARRS pharmacist sharing, premises decisions, premises money, capitation differences. The CD chairs the room. The CD also delivers the bad news afterwards.

Workforce decisions. Which ARRS roles to recruit. Which practices get the first pharmacist. How supervision is shared. What happens when a role leaves mid-year and the reimbursement schedule shifts. The decision sits with the CD.

ICB and commissioner-facing work. Funding bids. Service redesign meetings. Quality assurance returns. Innovation funding applications. CQC alignment with PCN-level services. None of this is in the job description in detail. All of it lands on the CD.

Recruitment and onboarding. New ARRS roles. Replacing departing staff. Sign-off on contracts. Initial induction. The CD’s name is on the paperwork.

Crisis management. A safeguarding concern raised against a PCN staff member. A patient complaint that crosses practices. A whistleblowing event. Each one is a multi-day distraction.

The hours allocated to the role usually cover a quarter of the actual time it consumes. The remainder comes out of GP partner sessions, often unpaid.

Where the role breaks

Three patterns recur.

CD burnout. Sustained months of working at one and a half to twice the allocated sessions, while still trying to deliver GP clinical sessions. By month 14, attendance at PCN meetings becomes the first thing to slip. By month 18, the resignation is on the table.

Partner relationship damage. A CD who has had to deliver enough hard decisions across six partnerships ends up with strained relationships in their own practice. The home practice no longer wants them taking the role.

Drift. The PCN does what it has always done because the CD does not have the bandwidth to drive change. The annual PCN plan repeats the previous year’s, with the same gaps.

What good CD support looks like

The CDs who survive and deliver tend to have three things in place.

A PCN manager. Not a partial-FTE add-on. A named, paid-for PCN manager who handles the operational lift. The CD chairs strategic discussions. The manager runs the day-to-day.

Defined supervision for ARRS staff. A senior clinician separate from the CD who holds the supervision responsibility for the pharmacist, technician, social prescriber, and care coordinator cohort. The CD oversees. The senior clinician supervises.

Outsourced specialist work. ARRS pharmacist deployment, innovation funding bids, service evaluation. Areas where the work is specialist enough that internal capacity is rarely the right choice.

What to outsource

Three areas account for most of the gains.

ARRS pharmacist and technician deployment. The legwork of recruitment, supervision, governance, payroll, and clinical oversight is significant. An external partner takes the operational work and leaves the CD with the strategic call.

Innovation funding. Bid writing and project delivery are specialist skills. The CD’s time is more valuable on patient and partner-facing work than on grant applications.

Service evaluation. Required for ARRS reporting and innovation funding. Specialist data work. Almost always better done externally than internally.

Where we help

We work with PCNs to take the operational layer off the Clinical Director. ARRS pharmacist and technician deployment, supervision, governance, and reporting under one managed service. Innovation funding and service evaluation as separate workstreams.

Our PCN management support service covers the CD support side. Get in touch for a conversation.

The post PCN Clinical Director Pressures and How to Lighten Them appeared first on Virtual Pharmacist.